ReviewFrontiers in cardiovascular medicine2021
Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism.
Review in Frontiers in cardiovascular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Differences in Glycemic Abnormalities Between Primary Aldosteronism and Essential Hypertension: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2022Pooled it
- A controlled trial of percutaneous adrenal arterial embolization for hypertension in patients with idiopathic hyperaldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Trial
- Blood pressure patterns and cardio-renal complications in primary aldosteronism compared with essential hypertension in a tunisian population.Journal of human hypertension · 2026Article
- Primary aldosteronism and long-term outcomes using PAMO definition.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Assessment of MRI-Derived proton density fat fraction of total subcutaneous adipose tissue for discrimination primary aldosteronism subtypes.Endocrine · 2026Article
- Primary aldosteronism beyond laterality: integrating subtype assignment with outcome-oriented risk stratification.Frontiers in endocrinology · 2026Review
- Primary aldosteronism and obstructive sleep apnea in hypertension: interplay, target organ damage, and clinical management.Frontiers in endocrinology · 2026Review
- Correlation Between Thyroid Function Parameters and Aldosterone-Renin Ratio in Patients With Primary Aldosteronism and Their Association With Target Organ Damage.International journal of endocrinology · 2026Article
- Association between care by hypertension specialists and major adverse cardiovascular events in patients with uncontrolled hypertension.Frontiers in cardiovascular medicine · 2026Article
- Noninvasive evaluation of renal oxygenation by blood oxygenation level-dependent magnetic resonance imaging in patients with primary aldosteronism.Scientific reports · 2025Article
- Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism.BMC endocrine disorders · 2025Article
- Effect of Age on Aldosterone-Renin Ratio in Screening Primary Aldosteronism.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- The relationship between tissue inhibitor of metalloproteinases-1 and KCNJ5 mutation in aldosterone-producing adenoma patients.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Preoperative predictive indicators for resolution of hypertension in patients with unilateral primary aldosteronism: development of a nomogram model.Langenbeck's archives of surgery · 2025Article
- Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications.Frontiers in endocrinology · 2025Review
- Alterations of White Matter Microstructure in Primary Aldosteronism Patients With Normal Cognitive Functioning Using Diffusion Tensor Imaging.International journal of general medicine · 2025Article
- The Effects of Aldosterone on Hypertension-Associated Kidney Injury in a Tg-hAS Mouse Model.Biology · 2024Article
- Effects of different treatment modalities on cardiovascular disease in ARR-positive hypertensive patients.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Review
- Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism.Endocrine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism (PA) is the most common type of endocrine hypertension, and numerous experimental and clinical evidence have verified that prolonged exposure to excess aldosterone is responsible for an increased risk of cerebro-cardiovascular events and target organ damage (TOD) in patients with PA. Therefore, focusing on restoring the toxic effects of excess aldosterone on the target organs is very important to reduce cerebro-cardiovascular events. Current evidence convincingly demonstrates that both surgical and medical treatment strategies would benefit cerebro-cardiovascular outcomes and mortality in the long term. Understanding cerebro-cardiovascular risk in PA would help clinical doctors to achieve both early diagnosis and treatment. Therefore, in this review, we will summarize the cerebro-cardiovascular risk in PA, focusing on the TOD of aldosterone, including brain, heart, vascular system, renal, adipose tissues, diabetes, and obstructive sleep apnea (OSA). Furthermore, the various treatment outcomes of adrenalectomy and medical treatment for patients with PA will also be discussed. We hope this knowledge will help improve cerebro-cardiovascular prognosis and reduce the incidence and mortality of cerebro-cardiovascular events in patients with PA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.